Growth Hormone SecretagoguesWADA Prohibited
Tesamorelin
Synonyms: Egrifta, TH9507
Sequence: trans-3-hexenoic acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
Critical Safety & Regulatory Notice
Tesamorelin is classified as a regulated, unapproved, or research-only substance. Doping/Regulatory Status: FDA approved in 2010 (Egrifta). Strictly prohibited by WADA under Section S2.. Clinical safety profiles for human use are deficient or not approved.
History & Discovery Timeline
Tesamorelin was developed by Theratechnologies as a GHRH analog stabilized by a trans-3-hexenoic acid group, targeting lipodystrophy in HIV-infected patients.
What it is: It is a stabilized GHRH analog containing 44 amino acids with an added hexenoic acid group. It is classified as a Metabolic peptide (brand name Egrifta).
Proposed Mechanisms & Research Findings: It stimulates growth hormone synthesis and release, which subsequently increases IGF-1 levels, reducing visceral fat accumulation.
Regulatory & Safety Status: It is FDA approved for the treatment of visceral adiposity in HIV-associated lipodystrophy. Sourcing must be conducted via prescription; gray-market alternatives are dangerous.
Athletic & Anti-Doping Status: Strictly prohibited by WADA under Section S2 as a growth hormone releasing hormone.
Understanding Tesamorelin Key Facts
Primary Target System:NEUROENDOCRINE
Residue Count / Length:48 Amino Acids
Primary Action & Category:GHRH Receptor Agonist (Growth Hormone Secretagogues)
Primary Receptors:GHRH Receptor (GHRHR)
Figure 1: Detailed molecular mechanism pathways of Tesamorelin (click to enlarge).